Recent papers highlight that dual inhibition of MAO-B and acetylcholinesterase (AChE) presents a promising approach to such multitarget treatments, as these enzymes play pivotal roles in modulating dopaminergic and cholinergic neurotransmission, respectively, both critically impaired in PD pathology [3,4]. This evidence concerns the gene ACHE and Parkinson disease.